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The increasing resistance of bacteria to antibiotics is a significant threat to human health and is a direct result 
of the excessive and improper use of these 
drugs. In 2007, multidrug-resistant bact erial 
strains infected more than 400,000 people 
in Europe and 25,000 patients died from 
the infections [1]. ‘Superbugs’ also have 
considerable economic impact: extra hos-
pital costs and related productivity losses 
amount to more than €1.5 billion per year 
in the European Union. In the USA, infec-
tions caused by multidrug resistant bac-
teria lead to US$20 billion in additional 
health-care costs and US$35 billion soci-
etal costs annually [2]. The situation is 
about to get worse, as there are only a few 
drugs left to treat multidrug-resistant bac-
terial strains, and the first strains that are 
resistant to even these last-resort antibiotics 
have already emerged. Moreover, there is a 
dearth of genuinely novel antibiotics in the 
development pipeline.
Various proposals have been made to 
address the problem. These range from the 
more-prudent use of existing antibiotics or 
better hygiene, to providing incentives to the 
pharmaceutical industry to develop novel 
drugs. In addition, the use of bacteriophages, 
or phage therapies, to kill specific pathogens 
without harming the majority of harmless, 
commensal bacteria has received increas-
ing attention during the past decade, but little 
has been done to capitalize on this interest 
and implement phage therapies in the clinic.
The application of bacteriophages to 
treat infection dates back to around the 
1920s. Today, phage therapies are routinely 
used in countries such as Georgia and 
Poland, but countries in western Europe 
abandoned such therapy after the introduc-
tion of antibiotics. Only a handful of clinical 
trials are on going and some are taking place 
in countries where European regulatory 
standards do not apply. Elsewhere, phage 
therapies are only applied sporadically in 
specialized medical centres for the ad hoc 
treatment of patients with severe infections. 
At this time, the greatest hurdle to the medi-
cal use of bacteriophages in Europe is the 
lack of an appropriate regulatory framework 
that appreciates the concept and specif-
ics of this approach to support its applica-
tion in the clinic. Part of the problem is that 
whether phage therapies are medicinal 
products or something completely different 
is unclear under current European legisla-
tion. Implementation and regulation of their 
use is therefore challenging.
The current legal framework for the use of medicines in Europe is mainly dictated by European directive 
2001/83/EG, which outlines the European 
Community code relating to medicinal 
products for human use. This directive was 
passed into law more than 10 years ago. It 
defines any substance or combination of 
substances used to treat or prevent disease 
in humans as human medicinal products 
and, therefore, makes them subject to spe-
cific requirements relating to safety, quality 
and efficacy. How phage therapies should 
be defined remains in question.
Bacteriophages are viruses that spe-
cifically attack bacteria and can be used to 
control, treat or prevent infectious diseases 
(Sidebar A). By controlling bacterial over-
growth, bacteriophages can re-equilibrate 
the host–bacteria balance and consequently 
they can indirectly restore physiological 
functions and boost the immune system. 
According to the definitions in the direc-
tive and the national legislation based on 
it, bacteriophages could be considered to 
be human medicinal products. The con-
sequences of classifying them in this way 
would be far-reaching: phage therapies 
would require assessment in large clinical 
studies to demonstrate safety and efficacy. 
A strength of phage therapies is that they 
can be tailored to each patient and to each 
patient’s bacterial infection. This flexibility 
is not fully compatible with the approach of 
the directive. In fact, bacterio phages are not 
mentioned in the current legislation, and 
the technical assistance or documentation 
that could be used to prepare a regulatory 
dossier does not exist.
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“...there are only a few drugs 
left to treat multidrug-resistant 
bacterial strains, and the first 
strains that are resistant to even 
these last-resort antibiotics have 
already emerged”
“...the greatest hurdle to the 
medical use of bacteriophages 
in Europe is the lack of an 
appropriate regulatory 
framework that appreciates [its] 
concept and specifics...”
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Nevertheless, if we are to introduce phage therapy into clinical practice, they must be regulated according to 
the directive. To address its limitations, there-
fore, and in order to draft (Sidebar A) appro-
priate regulatory protocols for use, it is first 
necessary to define under which categ ory of 
human medicinal products bacterio phages 
fall. The first category includes conventional 
small molecules or synthetic human medici-
nal drugs, such as aspirin, that can be 
described and researched in a standardized 
manner. From a functional point of view, such 
products are not comparable to bacterio -
phages because they operate in entirely dif-
ferent ways. Bacteriophages kill their specific 
bacterial host cells through bacterial lysis, 
which causes the release of new bacterio-
phage virions. When the targeted bacterial 
density drops below the detection threshold, 
the bacteriophages are removed by the retic-
ulo-endothelial system and the therapeutic 
intervention becomes self-terminating. 
Also unlike standard drugs, bacteriophages 
mutate and co-evolve with their host bacteria, 
an evolutionary ‘arms race’.
The second category of biological 
human medicinal products, which includes 
vaccines, seems more suitable, but it does 
not encapsulate all the features of phage 
therapies. From a general structural point of 
view, a bacteriophage is a protein-encapsu-
lated nucleic acid genome. Moreover, they 
might be collected from a biological source, 
for example released from bacteria or col-
lected from a patient’s tissues or fluids (for 
instance from wounds) or from waste waters. 
Like vaccines, bacteriophage-based prod-
ucts used in humans need to be updated 
over time—especially when bacteria 
develop resistance—just as the flu-vaccine 
cocktail is tailored anew each year. 
Bacteriophages, however, do not produce 
active immunity against a specific pathogen 
as ‘regular’ vaccines do. Rather, they are 
antimicrobials, with a secondary com-
petence of boosting the immune system. 
As such, they are perhaps better considered 
as similar to therapeutic vaccines.
Therapeutic vaccines fall under a third 
category of human medicinal products, 
the advanced-therapy medicinal products 
(ATMPs). ATMPs are defined in directive 
2001/83/EC as complex therapeutic prod-
ucts for gene therapy, cell therapy or tissue 
regeneration, and have their own regulatory 
framework. Obviously, though, natural bac-
teriophages are not somatic cells or tissue- 
engineered medicinal products and are not 
natural products used in gene therapy, since 
they are not genetically modified.
The conclusion from the arguments 
presented above is that phage therapies 
should probably be classified as biologi-
cal human medicinal products, despite 
the poor fit with this classification. Phage 
therapies do not fit into a single category 
perfectly, but this choice would be in 
accordance with the current UK practice 
of classifying bacteriophages. 
“Isolating a bacteriophage 
to combat the infection, 
preparing a therapeutic dose and 
administering it to the patient 
needs to be done within days”
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If bacteriophages are regarded as human biological medicinal products, they must adhere to the relevant legal frame-
work: any therapy has to demonstrate safety 
and efficacy and conform to quality stand-
ards. Bacteriophages exist ubiquitously in 
the environment, including in the human 
body. They specifically infect certain bacte-
ria, but do not attack other bacterial strains 
or eukaryotic human cells. To assume that 
bacterio phages will be safe for therapeu-
tic use and ought not to require extensive 
studies that would delay their clinical use, 
therefore, seems appropriate. Even so, clini-
cians should prospectively collect and reg-
ister data and clinical outcomes of phage 
therapies to create a body of information for 
further research and on which applications 
can build.
In regard to efficacy and safety, only 
virulent, exclusively lytic phages are gen-
erally considered to be clinically useful 
because they kill their host cells and do not 
integrate into the bacterial host genome. 
Therefore, the presence of temperate 
bacterio phages must be strictly excluded. 
Detailed molecular characterization of the 
bacteriophage genome is also mandatory 
to exclude the presence of any toxin genes 
or antibiotic-resistance genes.
With respect to quality, a combination 
of physical, chemical and biological tests 
could be used to characterize bacterio-
phage-based products, together with stand-
ard quality control procedures applied to 
the production process. Bacteriophages 
should be produced in a non-pathogenic 
bacterial host and the final therapeu-
tic preparations must be pure (absent of 
residual contaminating bacteriophages 
and other host cells), sterile, apyrogenic and 
pH neutral [3]. Such a focused approach to 
guarantee safety, quality and efficacy could 
enable clinicians to quickly prepare phage 
therapeutics against severe infections with 
multi drug-resistant pathogens. 
The current regulatory regime for human biological medicinal prod-ucts, which implies the conduct of 
clinical trials and the submission of a full 
product dossier compliant with directive 
2001/83/EG, imposes expensive and time-
consuming overheads on the urgent devel-
opment of phage therapies. If we consider 
the example of a patient currently infected 
with a multidrug-resistant bacterial strain 
who needs immed iate treatment because 
antibiotics have failed, the need to conduct 
clinical trials and compile dossiers is not 
feasible within the time frame required to 
develop a targeted ad hoc therapy, and 
would not allow timely treatment of the 
patient. Isolation of a bacterio phage to com-
bat the infection, preparation of a therapeu-
tic dose and its administration to the patient 
needs to be done within days. Under the 
human biological medicinal product frame-
work, we would have to wait 8–10  years 
until clinical studies have demonstrated 
safety and efficacy.
Another problem is the massive cost 
of conducting clinical studies. Non-profit 
clinics and research institutes will not be 
able to shoulder the financial burden of 
a regulatory regime originally designed 
for drug development by pharmaceutical 
companies. Some companies, such as Eli 
Lilly, have invested in bacteriophage-based 
products or cocktails for human treatment, 
but the host-specificity of phage therapies 
excludes uniform production and clinical 
application. Large-scale production of natu-
ral bacteriophages might be helpful in some 
instances, such as in cases of epidemic 
outbreaks or in clinical programmes where 
phage cocktails are regularly updated, but 
the full therapeutic potential of natural 
bacterio phages can only really be exploited 
through a patient-specific approach.
The most likely places that patient-specific phage therapies would be administered are hospitals, in close 
collaboration with associated microbiologi-
cal laboratories that would select and iso-
late the most suitable bacteriophages. This 
approach would require a simplified regula-
tory framework, given that neither time nor 
money is available. From this perspective, 
bacteriophage therapy resembles the histori-
cal context of ATMPs, which were mainly 
developed at clinics and academic research 
institutions and were only recently brought 
under the human medicinal product legis-
lation (regulation 1394/2007). The legisla-
tion exempts hospitals from the regulatory 
framework if a cell therapy is applied under 
the direct supervision and prescription of a 
medical doctor for a specific patient (article 
28 of regulation [EC] No. 1394/2007), but 
for ATMPs, national rules apply instead.
As argued above, bacteriophages 
should probably be classified as human 
medicinal products. Unfortunately, direc-
tive 2001/83/EG does not provide a hos-
pital exemption for these. It does state, 
however, that it “shall not apply to any 
medicinal product prepared in a pharmacy 
in accordance with a medical prescrip-
tion for an individual patient (commonly 
known as the magi sterial formula)”. Even if 
this clause allowed hospitals to bypass the 
costly requirement to demonstrate safety 
and efficacy, hospital pharmacists can 
only use licensed products as components 
for magisterial preparations. Since natural 
bacteriophages are not licensed products, 
this regulatory bypass would be difficult 
to implement.
How then can the regulatory frame-work be adapted to allow hos-pitals to design and administer 
tailor-made phage therapies? Although 
regulators are responsible for applying 
regulations, a regulation itself can only be 
changed through legislative action. We 
suggest an adapted regulatory framework, 
inspired by the existing legislation govern-
ing ATMPs, which includes exemption for 
the hospital-based use of cell and gene 
products and therapies. Hospitals should 
be granted exemption for biological human 
medicinal products, accompanied by spe-
cific regulation for phage therapies devel-
oped from natural bacteriophages with 
regard to safety, potency, purity and toxi-
city. Pharmaceutical companies developing 
Sidebar A | Further reading
d’Herelle F (1917) C R Acad Sci 165: 373–375. 
In this historical paper, the first isolation 
of bacteriophages for use in treatment and 
prophylaxis of infectious diseases is described.
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The authors report on the growing body of 
literature describing the validation of the use of 
bacteriophages for therapy and prophylaxis in 
the war against drug-resistant bacteria.
Pirnay JP et al (2011) Pharm Res 28: 934–937. 
The authors stress the importance of a sur-
mesure approach for phage therapy.
Merabishvili M et al (2009) PLoS ONE 4: 1–10. 
A quality-controlled small-scale production of 
a well-defined bacteriophage cocktail for use in 
human clinical trials is described. 
“...the full therapeutic potential 
of natural bacteriophages can 
only really be exploited through 
a patient-specific approach”
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products based on natural bacterio phages 
would still have to abide by the normal 
regulations that apply to biological medi-
cinal products. Thus, such a regulatory 
framework would distinguish between the 
hospital-based (tailor-made) use of natural 
bacteriophages in patients and the indus-
trial production and distribution of uniform 
phage products. Quality and safety criteria 
would be specified and efficacy documen-
tation required, but it would allow treating 
physicians to fully exploit the coevolution-
ary aspects of natural bacterio phages for the 
benefit of patients (Sidebar A).
It is necessary to start talking to regula-
tors and legislators and persuade them of 
the prudence of a dedicated legal frame-
work for bacteriophage therapy. Doing 
nothing to address the growing bac-
terial resistance to antibiotics is not an 
option. Considering that more than 20,000 
European citizens die annually from 
untreatable bacterial infections, Europe and 
its member states should find the courage 
and creativity to financially, technically and 
legally support the introduction of phage 
therapies throughout Europe.
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